By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Labcyte today announced it has been awarded $196,000 from the National Cancer Institute for the development of a system for early cancer detection.

The funding will go toward a collaborative cancer biomarker validation program that aims to develop a system that integrates "a suite of well-established biotechnologies," including Labcyte's proprietary acoustic liquid handling for arraying and MALDI mass spectrometry preparation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.